Make an enquiry
Refer a patient
Pay my bill
0808 304 2332

We noticed you are on our UK page. Want to switch regions? Choose from the options:

AU
ES
GenesisCare - logo
Patients
Find a centre
Find a doctor
0808 304 2332
Make an enquiry
Refer a patient
Pay my bill

We noticed you are on our UK page. Want to switch regions? Choose from the options:

AU
ES
Find a centre
Find a doctor
0808 304 2332
2026-03-01T00:00:00.000+00:00

DS8201-772 Destiny

DS8201-772 Destiny
Ovarian cancer

Trial overview

Disease

Ovarian cancer

Sponsor

Daiichi Sankyo

Description

DS8201-772 Destiny Ovarian-01 A Phase 3, Open-label, Multicenter, Randomized Study of Trastuzumab ENGOT Ov89 Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First- line Maintenance Therapy in HER2-Expressing Ovarian Cancer

Study details

For detailed information on this trial, please click here

Trial status

Opening March 2026

Location

Oxford

Oxford :::

Principal Investigator

Dr. Rene Roux

You are leaving our website

You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.